nach oben

Clinical Rheumatology

Erschienen in:

11.07.2017 | Original Article

Circulating osteoprotegerin levels are elevated in rheumatoid arthritis: a systematic review and meta-analysis

verfasst von: Peng Wang, Si Li, Li-Na Liu, Tian-Tian Lv, Xiao-Mei Li, Xiang-Pei Li, Hai-Feng Pan

Erschienen in: Clinical Rheumatology | Ausgabe 10/2017

Einloggen, um Zugang zu erhalten

Abstract

This study aimed to systemically review the evidence regarding the relationship between the circulating blood osteoprotegerin (OPG) level and rheumatoid arthritis (RA), as well as the potential influential factors. Research related to plasma/serum OPG levels in RA patients and healthy controls were gathered using PubMed, EMBASE, and The Cochrane Library database (up to Jan. 1, 2017). Pooled standard mean difference (SMD) with 95% confidence interval (CI) was calculated by fixed-effects or random-effect model analysis. Heterogeneity test was performed by the Q statistic and quantified using I ², and publication bias was evaluated using a funnel plot and Egger’s linear regression test. After searching databases, 443 articles were obtained, and 11 studies with 710 RA patients and 561 controls were finally included. Meta-analysis revealed that, compared with the control group, the OPG level was significantly higher in the RA group (P < 0.001), with the SMD of 1.02 and 95%CI (0.20, 1.84). Subgroup analyses showed that race, disease duration, body mass index (BMI), and disease activity score based on the assessment of 28 joints (DAS28) were positively associated with OPG level in RA patients. Our meta-analysis revealed a significantly higher circulating OPG level in RA patients, and it was influenced by race, disease duration, BMI, and DAS28.

Rudan I, Sidhu S, Papana A, Meng SJ, Xin-Wei Y, Wang W, Campbell-Page RM, Demaio AR, Nair H, Sridhar D, Theodoratou E, Dowman B, Adeloye D, Majeed A, Car J, Campbell H, Wang W, Chan KY, Global Health Epidemiology Reference G (2015) Prevalence of rheumatoid arthritis in low- and middle-income countries: a systematic review and analysis. J Glob Health 5(1):010409. doi:10.7189/jogh.05.010409 CrossRefPubMedPubMedCentral

Usenbo A, Kramer V, Young T, Musekiwa A (2015) Prevalence of arthritis in Africa: a systematic review and meta-analysis. PLoS One 10(8):e0133858. doi:10.1371/journal.pone.0133858 CrossRefPubMedPubMedCentral

Van Doornum S, McColl G, Wicks IP (2002) Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 46(4):862–873. doi:10.1002/art.10089 CrossRefPubMed

Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D (2008) Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 59(12):1690–1697. doi:10.1002/art.24092 CrossRefPubMed

Romas E, Gillespie MT, Martin TJ (2002) Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 30(2):340–346CrossRefPubMed

Van Campenhout A, Golledge J (2009) Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 204(2):321–329. doi:10.1016/j.atherosclerosis.2008.09.033 CrossRefPubMed

Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA, Giachelli CM (2000) Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem 275(28):20959–20962. doi:10.1074/jbc.C000290200 CrossRefPubMed

Schoppet M, Al-Fakhri N, Franke FE, Katz N, Barth PJ, Maisch B, Preissner KT, Hofbauer LC (2004) Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Monckeberg’s sclerosis and atherosclerosis. J Clin Endocrinol Metab 89(8):4104–4112. doi:10.1210/jc.2003-031432 CrossRefPubMed

Albu A, Bondor CI, Craciun AM, Fodor D (2014) Circulating osteoprotegerin and asymptomatic carotid atherosclerosis in postmenopausal non diabetic women. Adv Med Sci 59(2):293–298. doi:10.1016/j.advms.2014.08.002 CrossRefPubMed

10.

Perez de Ciriza C, Moreno M, Restituto P, Bastarrika G, Simon I, Colina I, Varo N (2014) Circulating osteoprotegerin is increased in the metabolic syndrome and associates with subclinical atherosclerosis and coronary arterial calcification. Clin Biochem 47(18):272–278. doi:10.1016/j.clinbiochem.2014.09.004 CrossRefPubMed

11.

Makarovic S, Makarovic Z, Steiner R, Mihaljevic I, Milas-Ahic J (2015) Osteoprotegerin and vascular calcification: clinical and prognostic relevance. Collegium antropologicum 39(2):461–468PubMed

12.

Lopez-Mejias R, Ubilla B, Genre F, Corrales A, Hernandez JL, Ferraz-Amaro I, Tsang L, Llorca J, Blanco R, Gonzalez-Juanatey C, Gonzalez-Gay MA, Dessein PH (2015) Osteoprotegerin concentrations relate independently to established cardiovascular disease in rheumatoid arthritis. J Rheumatol 42(1):39–45. doi:10.3899/jrheum.140690 CrossRefPubMed

13.

Klimek E, Skalska A, Kwasny-Krochin B, Surdacki A, Sulicka J, Korkosz M, Fedak D, Kierzkowska I, Wizner B, Grodzicki TK (2014) Differential associations of inflammatory and endothelial biomarkers with disease activity in rheumatoid arthritis of short duration. Mediat Inflamm 2014:681635. doi:10.1155/2014/681635 CrossRef

14.

Sunal KS (2015) Evaluation of various factors leading to osteolytic and antiosteolytic effects in patients with rheumatoid arthritis. Archives of Rheumatology 30(1):45–50. doi:10.5606/ArchRheumatol.2015.4908 CrossRef

15.

Asanuma Y, Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani A, Raggi P, Sokka T, Pincus T, Stein CM (2007) Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis. Atherosclerosis 195(2):e135–e141. doi:10.1016/j.atherosclerosis.2007.04.049 CrossRefPubMedPubMedCentral

16.

Xu S, Wang Y, Lu J, Xu J (2012) Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis. Rheumatol Int 32(11):3397–3403. doi:10.1007/s00296-011-2175-5 CrossRefPubMed

17.

Liu YY, Long L, Wang SY, Guo JP, Ye H, Cui LF, Yuan GH, Li ZG (2010) Circulating Dickkopf-1 and osteoprotegerin in patients with early and longstanding rheumatoid arthritis. Chin Med J 123(11):1407–1412PubMed

18.

Nakken B, Szodoray P (2010) Accelerated atherosclerosis in rheumatoid arthritis: rationale for mannose-binding lectins? J Rheumatol 37(3):482–484. doi:10.3899/jrheum.091364 CrossRefPubMed

19.

Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558. doi:10.1002/sim.1186 CrossRefPubMed

20.

Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560CrossRefPubMedPubMedCentral

21.

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634CrossRefPubMedPubMedCentral

22.

Delgado-Frias E, Lopez-Mejias R, Genre F, Ubilla B, Gomez Rodriguez-Bethencourt MA, Gonzalez-Diaz A, de Vera-Gonzalez AM, Gonzalez-Rivero AF, Diaz-Gonzalez F, Gonzalez-Gay MA, Ferraz-Amaro I (2015) Relationship between endothelial dysfunction and osteoprotegerin, vitamin D, and bone mineral density in patients with rheumatoid arthritis. Clin Exp Rheumatol 33(2):241–249PubMed

23.

Beyazal MS, Erdogan T, Devrimsel G, Turkyilmaz AK, Cure MC, Beyazal M, Sahin I (2016) Relationship of osteoprotegerin to pulse wave velocity and carotid intima-media thickness in rheumatoid arthritis patients. Z Rheumatol 75(7):723–728. doi:10.1007/s00393-015-1675-1 CrossRefPubMed

24.

Swierkot J, Gruszecka K, Matuszewska A, Wiland P (2015) Assessment of the effect of methotrexate therapy on bone metabolism in patients with rheumatoid arthritis. Arch Immunol Ther Exp 63(5):397–404. doi:10.1007/s00005-015-0338-x CrossRef

25.

Ghorbanihaghjo A, Hajialilo M, Shahidi M, Khabazi A, Kolahi S, MRJ N, Raeisi S, Argani H, Rashtchizadeh N (2014) Osteoprotegerin (OPG) and matrix Gla protein (MGP) in rheumatoid arthritis patients: relation to disease activity. The Egyptian Rheumatologist 36(3):111–116. doi:10.1016/j.ejr.2014.01.003 CrossRef

26.

Long L, Liu Y, Wang S, Zhao Y, Guo J, Yu P, Li Z (2010) Dickkopf-1 as potential biomarker to evaluate bone erosion in systemic lupus erythematosus. J Clin Immunol 30(5):669–675. doi:10.1007/s10875-010-9436-z CrossRefPubMed

27.

Buzi F, Maccarinelli G, Guaragni B, Ruggeri F, Radetti G, Meini A, Mazzolari E, Cocchi D (2004) Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner’s syndrome and rheumatoid arthritis. Clin Endocrinol 60(1):87–91CrossRef

28.

Engvall IL, Svensson B, Boonen A, van der Heijde D, Lerner UH, Hafstrom I, BARFOT study group (2013) Low-dose prednisolone in early rheumatoid arthritis inhibits collagen type I degradation by matrix metalloproteinases as assessed by serum 1CTP—a possible mechanism for specific inhibition of radiological destruction. Rheumatology (Oxford) 52(4):733–742. doi:10.1093/rheumatology/kes369 CrossRef

29.

Lange U, Dischereit G, Tarner I, Frommer K, Neumann E, Muller-Ladner U, Kurten B (2016) The impact of serial radon and hyperthermia exposure in a therapeutic adit on pivotal cytokines of bone metabolism in rheumatoid arthritis and osteoarthritis. Clin Rheumatol 35(11):2783–2788. doi:10.1007/s10067-016-3236-7 CrossRefPubMed

30.

Glass DA 2nd, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, Karsenty G (2005) Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8(5):751–764. doi:10.1016/j.devcel.2005.02.017 CrossRefPubMed

31.

Dhore CR, Cleutjens JP, Lutgens E, Cleutjens KB, Geusens PP, Kitslaar PJ, Tordoir JH, Spronk HM, Vermeer C, Daemen MJ (2001) Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 21(12):1998–2003CrossRefPubMed

32.

Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J (2004) Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109(18):2175–2180. doi:10.1161/01.CIR.0000127957.43874.BB CrossRefPubMed

33.

Dessein PH, Lopez-Mejias R, Gonzalez-Juanatey C, Genre F, Miranda-Filloy JA, Llorca J, Gonzalez-Gay MA (2014) Independent relationship of osteoprotegerin concentrations with endothelial activation and carotid atherosclerosis in patients with severe rheumatoid arthritis. J Rheumatol 41(3):429–436. doi:10.3899/jrheum.131037 CrossRefPubMed

34.

Genre F, Lopez-Mejias R, Miranda-Filloy JA, Ubilla B, Carnero-Lopez B, Palmou-Fontana N, Gomez-Acebo I, Blanco R, Rueda-Gotor J, Pina T, Gonzalez-Juanatey C, Llorca J, Gonzalez-Gay MA (2014) Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-alpha antagonist therapy. Clin Exp Rheumatol 32(5):640–646PubMed

35.

Ziolkowska M, Kurowska M, Radzikowska A, Luszczykiewicz G, Wiland P, Dziewczopolski W, Filipowicz-Sosnowska A, Pazdur J, Szechinski J, Kowalczewski J, Rell-Bakalarska M, Maslinski W (2002) High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 46(7):1744–1753. doi:10.1002/art.10388 CrossRefPubMed

36.

Kubota A, Hasegawa K, Suguro T, Koshihara Y (2004) Tumor necrosis factor-alpha promotes the expression of osteoprotegerin in rheumatoid synovial fibroblasts. J Rheumatol 31(3):426–435PubMed

37.

Remuzgo-Martinez S, Genre F, Lopez-Mejias R, Ubilla B, Mijares V, Pina T, Corrales A, Blanco R, Martin J, Llorca J, Gonzalez-Gay MA (2016) Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis. Sci Rep 6:29713. doi:10.1038/srep29713 CrossRefPubMedPubMedCentral

38.

Shen Y, Jiang T, Wang R, He S, Guo M, Zuo J, He D (2015) (5R)-5-Hydroxytriptolide (LLDT-8) inhibits osteoclastogenesis via RANKL/RANK/OPG signaling pathway. BMC Complement Altern Med 15:77. doi:10.1186/s12906-015-0566-y CrossRefPubMedPubMedCentral

39.

Sennels H, Sorensen S, Ostergaard M, Knudsen L, Hansen M, Skjodt H, Peters N, Colic A, Grau K, Jacobsen S (2008) Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor-kappa B ligand, and high-sensitivity C-reactive protein in patients with active rheumatoid arthritis randomized to etanercept alone or in combination with methotrexate. Scand J Rheumatol 37(4):241–247. doi:10.1080/03009740801910320 CrossRefPubMed

Titel: Circulating osteoprotegerin levels are elevated in rheumatoid arthritis: a systematic review and meta-analysis
verfasst von: Peng Wang
Si Li
Li-Na Liu
Tian-Tian Lv
Xiao-Mei Li
Xiang-Pei Li
Hai-Feng Pan
Publikationsdatum: 11.07.2017
Verlag: Springer London
Erschienen in: Clinical Rheumatology / Ausgabe 10/2017
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-017-3747-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2017

Metabolic syndrome in patients with ankylosing spondylitis receiving anti-TNFα therapy: association with predictors of cardiovascular risk

Mycophenolate mofetil and deflazacort combination in neuropsychiatric lupus: a decade of experience from a tertiary care teaching hospital in southern India

Erratum to: Serious adverse events after HPV vaccination: a critical review of randomized trials and post-marketing case series

Re: Did King Herod suffer from a rheumatic disease? doi: 10.1007/s10067-017-3583-z

Diffusion tensor imaging of mild-moderate carpal tunnel syndrome: correlation with nerve conduction study and clinical tests